The pre-BCR consists of Ig m protein, the product of a heavy chain gene assembled by V(D)J recombination in pro-B cells, the surrogate light chains V pre-B and l5, and the signaling chains Iga and Igb. Signaling by the pre-BCR is a checkpoint required for further maturation of pro-B cells in the adult bone marrow. However, it is currently not known whether an extracellular ligand is required to initiate pre-BCR signaling. We reasoned that if the ectodomain of the pre-BCR is required to interact with a ligand, then a truncated heavy chain protein would not support B cell development. To test this notion, we produced transgenic mice expressing a heavy chain protein whose extracellular domains except for C H 4 were replaced by an irrelevant Ig superfamily ectodomain from the human CD8a protein. This transgene resulted in pre-BCR-like signaling since it rescued development of pre-B cells in recombinase-activating gene (RAG)1-de®cient mice and resulted in allelic exclusion of the endogenous Ig heavy chain gene in RAG-pro®cient mice. These ®ndings lead us to suggest that the majority of the extracellular region of the pre-BCR is not required for pre-BCR function and, thus, ligand binding is unlikely to be required for pre-BCR function.
Introduction
Lymphoid development is characterized by the highly regulated assembly of antigen receptor genes from their component gene segments via a process known as V(D)J recombination. In developing B cells, the Ig heavy chain (IgH) locus rearranges before the Ig light chain loci, with D-to-J H rearrangement preceding V-to-DJ H rearrangement. In developing T cells, the TCRb locus rearranges before the TCRa locus, with D-to-J b rearrangement preceding V-to-DJ b rearrangement. If IgH or TCRb chain rearrangement results in an`in-frame' allele, Ig light chain or TCRa chain rearrangement is activated and further IgH or TCRb chain rearrangement ceases. This latter observation contributes to a molecular explanation of the well-known phenomenon of allelic exclusionÐan individual B or T cell expresses only one functional antigen receptor.
Expression of IgH or TCRb chain protein marks a critical checkpoint in B and T cell development. Previous work has shown that these chains assemble into a plasma membraneassociated structure known as the pre-BCR or pre-TCR consisting of surrogate light chains (V pre-B and l5) or surrogate a chain (pre-Ta) and the accessory chains Iga, Igb or the CD3 complex respectively [reviewed in (1±3)]. Mutation in any component of the pre-antigen receptor complexes results in a block in progression of development in that lineage. Therefore, understanding how the pre-BCR and pre-TCR transmit their signals is critical for understanding ordered gene rearrangement and allelic exclusion.
It is possible that a ligand exists in the developing cell environment which activates pre-BCR or pre-TCR signaling. Alternatively, signaling may be triggered by plasma membrane assembly of the receptor complex itself without need for an exogenous ligand. There is strong support for this latter notion with respect to the pre-TCR. Developing thymocytes expressing truncated mutant TCRb and pre-Ta chains containing only af®nity tags in place of their ectodomains nonetheless support apparently normal T cell development (4) . The situation in developing B cells is less clear. Our group and others have shown that a truncated heavy chain transgene, incapable of binding surrogate light chains, can nonetheless promote the pro-B to pre-B transition (5, 6) . It remained possible, however, that a putative pre-BCR ligand could interact with the C H 2, C H 3 or C H 4 domains of heavy chain protein remaining in those truncated heavy chain transgenic proteins. In order to clarify the potential role of a ligand in pre-BCR signaling, we have analyzed a new transgenic mouse line which expresses a chimeric heavy chain transgene encoding a protein consisting of the human CD8a (huCD8a) ectodomain fused to the membrane proximal portion of C H 4 and the m chain transmembrane exons. We ®nd that in a fashion similar to the truncated pre-TCR noted above, the huCD8a±m transgene promotes the pro-B to pre-B transition, indicating that pre-BCR signaling is independent of extracellular ligand.
Methods

Construction of plasmids
An EcoRI±XhoI restriction fragment of pHCMV-CD8/m4m (7), a gift from A. Venkitaraman (CIMR, Cambridge, UK), encoding the huCD8±m chimera was blunted with the Klenow fragment of DNA polymerase I and cloned into a blunted AccI site in the E m V H expression vector (8) . The resulting E m V H ±huCD8±m expression cassette was then¯anked by tandem pairs of the chicken b-globin insulator by cloning it (in place of the g-neo cassette) into the BamHI site of pJC13-1 (9), a gift of A. Bell and G. Felsenfeld (NIH, Bethesda,, MD). Prior to insertion of E m V H ±huCD8±m, pJC13-1 was ®rst modi®ed by removing the 5¢ HS2 mouse globin LCR from the EcoRI site, blunting the EcoRI site using Klenow DNA polymerase and replacing it with a SalI linker (NEB, Beverly, MA).
Production and maintenance of transgenic mice
A 13 kb SalI±SalI fragment containing the doubly insulated E m V H ±huCD8±m expression cassette was microinjected into the pronuclei of C57/BL6 Q C3H zygotes (Johns Hopkins University School of Medicine Transgenic Core Facility, Baltimore, MD). Founder huCD8±m transgenic mice were identi®ed by PCR and Southern analysis of genomic DNA from tail. Founder huCD8±m transgenic mice were bred to recombinase-activating gene (RAG)1-de®cient mice (10) and in some cases to b2-microglobulin (b 2 m)-de®cient mice (Jackson Laboratories, Bar Harbor, ME). The mice were housed in microisolator cages according to NIH guidelines.
Genotyping
PCR assays were used to determine the genotype of each mouse as previously described (6) . Below are sequences of PCR primers not previously described: huCD8±m transgene (T = 62°C): HCD8L, 5¢-GAC AGT GGA GCT GAA GTG CC; HCD8R, 5¢-GGC TGC GAC GCG ATG GTG; b 2 m knockout (T = 56°C): b 2 mL, 5¢-ACT CAC GCC ACC CAC CGG AG; b 2 mR, 5¢-GAT GCT GAT CAC ATG TCT CG. PCR cycling conditions were 94°C for 1 min; T annealing (as noted for each primer set above in parentheses) for 1 min; 72°C for 2 min, for 30 cycles.
Flow cytometric analysis of primary cells
Single-cell suspensions of bone marrow or spleen were stained for¯ow cytometry using the following antibodies (puri®ed from hybridoma supernatant in this laboratory or purchased from PharMingen, San Diego, CA, Sigma, St Louis, MO or Ortho-Diagnostics, Raritan, NJ): CD19 (1D3), B220 (RA3-6B2), m (331.2), CD43 (S7), huCD8a (UCHT-4 or OKT-8). The antibodies were either conjugated to FITC, phycoerythrin or biotin. Biotinylated antibodies were revealed using streptavidin±Quantum Red (Sigma). Antibody to mouse MHC I (II/41) was a gift from M. Soloski (Johns Hopkins). Stained cells were analyzed with a Becton Dickinson (Mountain View, CA) FACScan and CellQuest software. Dead cells were excluded by gating on live lymphocytes using forward and side scatter.
PCR analysis of V(D)J gene rearrangement and double-strand DNA breaks
Assays were performed as previously described (6) .
Results
Expression of a chimeric huCD8±m transgene in developing B cells
Previous studies had shown that a chimeric protein consisting of the entire ectodomain of hCD8a and the C H 4 and transmembrane domains of the Ig m heavy chain is expressed on the surface of transfected B cell lines in association with the signaling molecules Iga and Igb (7) . In order to determine the role of the V H and C H 1±3 domains of Ig heavy chain protein in B cell development, we generated transgenic mice using this huCD8±m cDNA and the B cell-speci®c expression vector E m V H (8) . The presumed structure of a huCD8±m-containing pre-BCR is shown in Fig. 1 in comparison with the wild-type pre-BCR and a previously studied truncated pre-BCR (6) .
Founders positive for the transgene were bred to RAG1-de®cient mice through two generations, and bone marrow and spleen puri®ed from various individual pups were analyzed for transgene expression using an anti-huCD8 antibody and¯ow cytometry (Fig. 2) . We found that a signi®cant fraction of B lineage (CD19 + ) bone marrow cells (~50%) and a small fraction of splenic B cells (B220 + ; 2.6±18%) in both a RAG1 ±/± and RAG1 +/± background expressed the transgene.
huCD8±m expression facilitates differentiation of pro-B cells to pre-B cells
The pro-B to pre-B cell transition in B cell development is characterized by changes in cell surface expression of CD43 and CD2. RAG1 ±/± B cell progenitors are arrested at the CD43 + CD2 ± stage of development (11±14). Expression of a fulllength wild-type m transgene in RAG1 ±/± mice causes these cells to progress to the pre-B cell stage (CD43 ± CD2 + ) (10, 15) . Similarly, we found that expression of huCD8±m resulted in the loss of CD43 expression and the acquisition of CD2 expression (Fig. 3) . In order to assess the ef®ciency of huCD8±m in promoting the pro-to pre-B cell transition in RAG ±/± mice, we compared the number of pro-B (CD19 + CD43 + ) and pre-B (CD19 + CD43 ± ) cells in groups of RAG ±/± , RAG ±/± huCD8±m and RAG ±/± wild-type±m transgenic mice (Table 1 ). This analysis revealed that the mutant and wild-type±m transgenes were quantitatively similar in their ability to promote the pro-to-pre B transition. These observations lead us to conclude that the pre-BCR signal resulting in alterations in surface marker expression is independent of the V H , C H 1, C H 2 and C H 3 domains of m, and of the surrogate light chains.
Although the chimeric huCD8a protein lacks V H and C H 1±3 domains, it remained possible that murine MHC class I molecules on the surface of bone marrow cells might serve as an arti®cial ligand for the huCD8±m pre-BCR. In order to test this idea, we bred the huCD8±m transgene onto the b 2 m ±/± genetic background which is de®cient in MHC class I expression (16, 17) . b 2 m de®ciency resulted in a nearly 40-fold decrease in surface MHC class I expression (data not shown), but did not alter the ability of the huCD8±m transgene to promote the pro-to pre-B transition (Fig. 4A ). Given the failure of diminished MHC class I expression to effect transgenic B cell development, we conclude that MHC class I molecules are very unlikely to serve as ligand for the huCD8a-containing pre-BCR.
HuCD8±m expression results in the allelic exclusion of endogenous IgH gene rearrangement
Expression of a transgenic wild-type heavy chain gene in developing B cells results in the allelic exclusion of endogenous IgH gene assembly (18, 19) . We analyzed the huCD8±m transgenic mice to determine whether expression of this chimeric protein likewise results in allelic exclusion. We stained bone marrow cells from huCD8±m transgenic and various control mice with anti-B220 and anti-m antibodies. The anti-mouse m monoclonal used in these studies does not recognize the huCD8±m chimera. Flow cytometric analysis revealed that the huCD8±m transgene suppressed surface expression of endogenous m in the bone marrow (Fig. 5) . Interestingly, we did observe signi®cant endogenous heavy chain expression in splenic B cells from RAG1 +/± huCD8±m transgenic mice. Allelic exclusion mediated by the huCD8±m transgene did not depend upon b 2 m expression since we observed indistinguishable and greatly diminished IgM expression in both b 2 m +/± and b 2 m ±/± huCD8±m transgenic mouse bone marrow (Fig. 4B) .
The ability of the huCD8±m transgene to block surface expression of endogenous heavy chain in the bone marrow might occur at the level of heavy chain gene assembly or at the level of heavy chain protein expression. To elucidate the mechanism of this effect, we puri®ed genomic DNA from transgenic and non-transgenic bone marrow, and performed a PCR analysis of V-to-DJ H rearrangement (Fig. 6 ). While The full-length m heavy chain transgene encodes a productive variable domain (VDJ H ), four constant domains (C H 1±4) and a transmembrane domain (TM) followed by a 3-amino-acid residue cytoplasmic tail. This wild-type heavy chain associates with the surrogate light chains (V pre-B and l5) and the signal transduction machinery (Iga and Igb) to form a wild-type pre-BCR as depicted. The stoichiometry of the m heavy chain homodimer to Iga:Igb heterodimer is depicted as 1:1 in the pre-BCR as it has been shown to be in the mature BCR (32) . (Middle) The truncated m heavy chain transgene is encoded by a DSP2 D H segment rearranged to a J H 3 segment (DJ H 3) ligated to a 5¢ truncated C H 2 exon and the remainder of the heavy chain coding exons (31) . Since this truncated m heavy chain is missing most of its V H and all of the C H 1 regions, it does not interact with V pre-B or l5. (Right) The huCD8±m chimera transgene is encoded by the extracellular region of human CD8a fused to the C H 4 exon and the remainder of the heavy chain coding exons (7) . The huCD8a ectodomain is structurally similar to variable Ig domains and facilitates homodimerization of the chimeric chain through its native interchain disul®de bridge.
huCD8±m transgenic and control mice had similar levels of DJ H -rearranged alleles, multiple individual mice from two distinct huCD8±m founders showed a striking decrease in VDJ H -rearranged alleles.
Assays which measure the abundance of rearranged alleles provide only an indirect measure of the targeting of the V(D)J recombinase to particular loci since cells containing speci®c rearranged alleles might undergo proliferation or death based on the structure of their encoded heavy chain protein. In order to more directly measure the effect of the huCD8±m transgene on regulation of the V(D)J recombinase, we used a ligationmediated PCR (LM-PCR) assay which detects doublestranded DNA breaks at recombination signal sequences (RSS) (Fig. 7A) (20) . These RSS breaks are recombination reaction intermediates whose presence indicates active recombination at a given locus. As shown in Fig. 7(B) , we were able to detect double-stranded DNA breaks 5¢ of DJ gene segments in non-transgenic bone marrow (Fig. 7B , lane 4) and in bone marrow from mice which failed to express the transgene (Fig. 7B, lane 5) . In contrast, we were unable to detect any 5¢ of DJ breaks in bone marrow from ®ve individual huCD8±m-expressing mice from two different founders (Fig. 7B, lanes 6±10 ). These same transgenic bone marrow DNA samples did contain double-stranded DNA breaks 5¢ of J k 1 (data not shown) and J k 5 (Fig. 7B, lanes 6±10) . We conclude from this experiment that transgene expression results in the allelic exclusion of endogenous IgH gene rearrangement.
Discussion
The pre-BCR mediates a critical checkpoint in early B cell development, signaling success in the assembly of a gene encoding a functional, properly folded Ig heavy chain. The nascent pre-B cell undergoes several rounds of cell division, then exits the cell cycle and activates Ig k locus rearrangement (1,2). A critical question in understanding the role of this receptor in mediating the pro-to pre-B transition is whether its function requires interaction with an extracellular ligand. It is possible that, distinct from other receptor systems, the pre-BCR is not designed to assess signals from the environment. Rather, its role may be to verify functional IgH gene assembly. Alternatively, it is possible that in addition to assessing the presence of a heavy chain, pre-B cells might undergo selection for the ability of the pre-BCR to recognize speci®c structures in their developing environment. These interactions might lead to deletion (or editing) of self-speci®c cells or positive selection of cells expressing potentially useful heavy chain structures. Fig. 2 . Flow cytometric analyses of huCD8±m transgene expression in bone marrow and spleen. Single-cell suspensions of whole bone marrow and spleen were prepared from RAG1-de®cient (RAG ±/± ), RAG1-heterozygous huCD8±m transgenic (RAG +/± huCD8±m) and RAG1-de®cient huCD8±m transgenic (RAG ±/± huCD8±m) mice. Cell surface expression of the pan-B cell markers CD19 or B220 was analyzed by¯ow cytometry after staining with the appropriatē uorochrome-conjugated antibody (see Methods). Cell surface expression of the huCD8±m was detected by a mAb against human CD8a (hCD8a). Electronic gating based on forward and side scatter was employed to select for live lymphocytes. Quadrant statistics based on the live lymphocyte gate are indicated in the top righthand corner of each FACS plot. (Upper panels) huCD8±m transgene expression in the indicated bone marrow samples. (Lower panels) huCD8±m transgene expression in the indicated spleen samples. Fig. 3 . Expression of the huCD8±m transgene promotes the pro-to pre-B cell transition in the bone marrow. Single-cell suspensions of whole bone marrow were prepared from RAG1-de®cient (RAG ±/± ), RAG1-heterozygous huCD8±m transgenic (RAG +/± huCD8±m) and RAG1-de®cient huCD8±m transgenic (RAG ±/± huCD8±m) mice. Values shown are the averages and SD from n mice (two hind legs per mice). Subpopulations were enumerated by FACS. For the top panel, mice were 6±8 weeks old. For the bottom panel, mice were 6 months old.
The current work, as well as previous studies from our laboratory and others (5, 6) , has shown that the variable domain of the pre-BCR is dispensable for its function. These observations make it very unlikely that the variable domain of the pre-BCR mediates an essential positive selection step based on extracellular ligand binding. This, however, does not rule out the possibility that the pre-B cell repertoire is in¯uenced by variable domain interactions. For example, it is possible that speci®c variable domain structures promote enhanced pre-B cell proliferation, resulting in an increased representation of that heavy chain in the immune repertoire. There is some evidence for such a positive selection step at the pre-B cell stage in the development of B1 B cells (21) . In addition, Hardy et al. have noted distinct effects on survival of various heavy chain transgenes in fetal as compared to adult pre-B cells (22) .
The present study was initiated in an attempt to understand how the pre-BCR might signal in the absence of its variable domain (6) . The C H 2 and C H 3 domains of soluble Ig mediate binding of Ig to Fc receptors expressed on the surfaces of various cell types including B cells themselves. The experiments presented here rule out a necessary interaction between these domains on the pre-BCR and Fc receptor since the huCD8±m transgene lacks the C H 2 and C H 3 domains. A recent report demonstrated that the B cell costimulatory molecule CD19 is capable of speci®c binding to IgM, but not to IgG (23). Therefore, it is possible that interaction between CD19 and the m heavy chain within the pre-BCR might play a role in pre-BCR signaling. Our ®nding that almost the entire ectodomain of the m chain is dispensable for pre-BCR signaling makes such a role for CD19 unlikely. Furthermore, CD19-de®cient mice do not display an obvious defect in pre-BCR signaling (24, 25) . While a necessary interaction with the variable, C H 1, C H 2 and C H 3 domains of m can be ruled out by our data, it remains possible that a putative pre-BCR ligand might interact with the ectodomains of either Iga or Igb.
If the pre-BCR (and similarly the pre-TCR) does not require extracellular ligand engagement, how then does it signal? We favor a model presented in greater detail elsewhere in which signaling depends only on membrane localization of the pre-BCR, and the relative levels of protein tyrosine phosphatases and kinases (1) . Surface transport of the pre-BCR, perhaps consequent to its localization in lipid rafts (26) , results in the occasional interaction of kinases (Lyn, Fyn or Blk) and subsequent tyrosine phosphorylation of ITAMs on Iga, Igb and signaling scaffolds leading to the recruitment of Syk. We propose that early in B cell development, the phosphatases which diminish the sensitivity of the BCR in mature cells are poorly expressed or not membrane associated, thus resulting in a milieu favoring receptor activity. Only minimal interaction between pre-BCR complexes is required to trigger the pre-BCR signal. Later in development, the level of phosphatases might increase, resulting in a requirement for BCR crosslinking in order to trigger a signal. Observations regarding the biochemical function and developmental regulation of the B cell surface molecule CD22 are consistent with this hypothesis (27, 28) . CD22 is a transmembrane protein whose large cytoplasmic domain contains an ITIM which inducibly interacts with the protein tyrosine phosphatase SHP-1. CD22 is amongst the small set of membrane proteins which become tyrosine phosphorylated immediately after BCR cross-linking. Co-cross-linking of CD22 with the BCR strikingly inhibits the BCR signal (29) . CD22 is developmentally regulated, with surface expression beginning at the late pre-B cell stage of development (28) . Thus, the absence of CD22 upon initial pre-BCR expression might allow for signaling with extrinsic cross-linking, whereas later in development, the presence of CD22 must be overcome by a greater degree of BCR aggregation such as that induced by ligand engagement. Additional data consistent with our model was provided by an analysis of the effects of SHP-1 mutation (the motheaten me v allele) on B cell tolerance. These studies showed that diminished phosphatase activity clearly alters the signaling threshold of the BCR (30) .
It is important to consider whether mutant transgenes provide a valid model with which to study the structural requirements for the pre-BCR signal. It is possible that any particular mutant heavy chain might fold in such a way as to enhance its artifactual aggregation on the cell surface. Such aggregated protein might signal constitutively by clustering Fig. 6 . Expression of the huCD8±m transgene results in a decreased frequency of VDJ H rearranged IgH alleles in transgenic mice. Genomic DNA samples were puri®ed from cells described below and equivalent amounts were used as template in PCR assays. Water (lane 1) and genomic DNA from 63-12, a RAG2-de®cient pro-B cell line (lane 3), serve as negative controls for rearrangements. Genomic DNA from spleen of a 4-day-old mouse (lane 2) and wildtype bone marrow from a 6-week-old non-transgenic littermate (lane 4) serve as positive controls for rearrangements. All genomic DNA samples from huCD8±m transgenic mice were isolated from bone marrow cells (lanes 5±10). Mouse #1 from the founder line 568-2 (lane 5) carries the transgene, but does not express it at the protein level (data not shown). Multiple samples of genomic DNA from two independent lines of CD8±m transgenic mice that did express the transgene were analyzed: three mice from founder line 577-1 (lanes 6±8) and two mice from line 577-3 (lanes 9 and 10). (Upper panel) Result of an assay for D-to-J H rearrangements. (Middle panel) Result of an assay for V-to-DJ H rearrangements. For the rearrangement PCR assays, products were separated by gel electrophoresis, blotted to nylon membranes, hybridized with radioactive probes speci®c for the products and revealed using a PhosphorImager. PCR ampli®cations of the CD14 gene were used to con®rm that the quality and amount among the genomic DNA samples were similar (bottom panel). associated Iga and Igb molecules. Although we cannot rule out such a model, we believe it to be unlikely for two reasons. First, immuno¯uorescence analysis of a signaling transgenic mutant heavy chain protein shows a pattern of surface expression indistinguishable from that of wild-type heavy chain protein (6) . Second, if the huCD8±m protein was aggregating on the cell surface, we would expect it to undergo capping and be eliminated from the cell surface. This is clearly not the case. Ultimately, biophysical studies will be required to rule out this possibility.
Finally, the ability of the huCD8±m transgene to enforce allelic exclusion is incomplete since sIgM + B cells do accumulate in the spleens of recombination competent transgenic mice (Fig. 5) . This was surprising given the signi®cant extent to which transgene expression decreases recombinase activity at the IgH locus as evidenced by the near absence of doublestranded DNA breaks 5¢ of DJ H alleles (Fig. 7) . We suggest that the explanation of this paradox is that rare developing B cells which do generate an endogenous functional IgH gene rearrangement are the only developing B cells to survive since they can go on to rearrange the k locus and generate a complete BCR. Recent work has shown that BCR expression is essential for B cell survival (31) . These rare cells presumably accumulate in the spleen leading to the observed results.
